A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy

• Status: Terminated
• Trial end date: 2009-10-26
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy and safety of ocrelizumab, compared to placebo, in patients with active rheumatoid arthritis who have an inadequate response to methotrexate therapy. Patients will be randomized 2:2:1 to receive 1) infusions of ocrelizumab 200mg iv on Days 1 and 15, 2) infusions of ocrelizumab 400mg iv on Day 1 and placebo iv on Day 15, or 3) infusions of placebo iv on Days 1 and 15. At the end of the placebo-controlled treatment period at 24 weeks, patients in groups 1 and 3 will be re-randomized to receive either a single infusion of 400mg iv ocrelizumab or 2 infusions of 200mg iv ocrelizumab, and group 2 will receive a second single infusion of 400mg iv ocrelizumab. All patients will receive a stable dose of concomitant methotrexate (7.5-25mg/week) throughout the study. The anticipated time on study treatment is 1-2 years. Target number of patients to be enrolled in this trial is 300.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genentech, Inc.
• Collaborator: Roche Pharma AG
• Treatments: Methotrexate; Ocrelizumab

Criteria

Inclusion criteria:

• Adult patients, ≥ 18 years of age

• Active rheumatoid arthritis

• Inadequate treatment with any DMARD other than methotrexate

Exclusion criteria:

• Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis

• Concurrent treatment with any DMARD other than methotrexate

• Previous treatment with any cell-depleting therapies

• Any surgical procedure in past 12 weeks, or planned within 48 weeks after baseline